The effective management of triple-negative breast cancer (TNBC) has been a decades-long challenge due to its aggressive nature and, as the name implies, the lack of estrogen (ER) and progesterone receptors (PR) and human epidermal growth factor receptor type 2 (HER2) as drivers, for which there are targeted, more effective therapies [1]. The gene discussed is PGR; the disease is triple-negative breast carcinoma.